Compliance Rate

Compliance Rate 0%
Compliant submissions 0
Incompliant submissions 0
Total trials 0

My Organizations' Clinical Trials

Showing 425 of 2529 entries
View as:

PROFILE - Evaluation of QoL and PRO Outcomes in Patients Taking Fingolimod

Phase: N/A Priority: Normal
NCT ID: NCT02335892 Org: User:
Start: 11/11/14 End: 02/01/17 Due: 02/01/18

This Was an Open-label, Single-arm Extension Study (CFTY720D2306E1) to a Double-blind, Randomized Multicenter, Placebo-controlled, Parallel-group Core Study (CFTY720D2306) in PPMS.

Phase: N/A Priority: Normal
NCT ID: NCT00731692 Org: User:
Start: 07/28/08 End: 06/22/15 Due: 06/22/16

Study in Patients With Untreated Multiple Myeloma and Renal Insufficiency

Phase: N/A Priority: Normal
NCT ID: NCT01337752 Org: User:
Start: 01/31/12 End: 05/31/13 Due: 05/31/14

A Safety, Tolerability and Efficacy Study in Chronic Obstructive Pulmonary Disease (COPD) Patients With QBM076.

Phase: N/A Priority: Normal
NCT ID: NCT01972776 Org: User:
Start: 11/30/13 End: 05/31/15 Due: 05/31/16

A Study to Assess the Wakefulness Promoting Effect, Safety, Tolerability, and Pharmacokinetics (PK) of LML134 in Shift Work Disorder

Phase: N/A Priority: Normal
NCT ID: NCT03141086 Org: User:
Start: 07/26/17 End: 09/12/18 Due: 09/12/19

Determining the Maximum Tolerated Dose of Low Dose Interferon-alpha in Conjunction With Nilotinib in Pretreated Philadelphia Chromosome Positive (Ph+) Chronic Myeloid Leukemia Patients in Chronic Phase (CML-CP)

Phase: N/A Priority: Normal
NCT ID: NCT01220648 Org: User:
Start: 04/30/12 End: 01/31/14 Due: 01/31/15

Non-interventional Study to Assess the Effectiveness and Safety of Ribociclib in the Adjuvant Therapy of Hormone Receptor Positive (HR+) HER2-negative Stage II and III Breast Cancer in Real Clinical Practice in Russia

Phase: N/A Priority: Normal
NCT ID: NCT06930859 Org: User:
Start: 07/31/25 End: 07/31/32 Due: 07/31/33

Systemic VEGF Protein Dynamics Following Intravitreal Injections of Ranibizumab Versus Aflibercept in Patients With Visual Impairment Due to Diabetic Macular Edema

Phase: N/A Priority: Normal
NCT ID: NCT02258009 Org: User:
Start: 10/31/15 End: 10/31/16 Due: 10/31/17

Study of Efficacy and Safety of Novel Spartalizumab Combinations in Patients With Previously Treated Unresectable or Metastatic Melanoma

Phase: N/A Priority: Normal
NCT ID: NCT03484923 Org: User:
Start: 09/10/18 End: 12/30/22 Due: 12/30/23

A Worldwide Antihistamine-Refractory Chronic Urticaria Patient Evaluation in Latin America and Canada (AWARE-LACan)

Phase: N/A Priority: Normal
NCT ID: NCT02626221 Org: User:
Start: 12/24/14 End: 03/21/18 Due: 03/21/19

Dose Finding and Safety of Oral LDE225 in Patients With Advanced Solid Tumors

Phase: N/A Priority: Normal
NCT ID: NCT00880308 Org: User:
Start: 03/31/09 End: 07/31/13 Due: 07/31/14

A Phase II Study to Evaluate the Efficacy of TKI258 for the Treatment of Patients With FGFR2 Mutated or Wild-type Advanced and/or Metastatic Endometrial Cancer

Phase: N/A Priority: Normal
NCT ID: NCT01379534 Org: User:
Start: 11/30/11 End: 03/31/14 Due: 03/31/15

Safety and Efficacy of TKI258 in Relapsed or Refractory Multiple Myeloma Patients, Who Are With or Without t(4;14) Chromosomal Translocation

Phase: N/A Priority: Normal
NCT ID: NCT01058434 Org: User:
Start: 05/31/10 End: 02/28/13 Due: 02/28/14

Study to Assess the Efficacy and Safety of Ruxolitinib in Patients With COVID-19 Associated Cytokine Storm

Phase: N/A Priority: Normal
NCT ID: NCT04362137 Org: User:
Start: 05/02/20 End: 10/17/20 Due: 10/17/21

Pilot Decentralized Clinical Trial in Men and Pre and Post-menopausal Women With Breast Cancer and a Specific Mutation (PIK3CA) Treated With Alpelisib in Combination With Fulvestrant

Phase: N/A Priority: Normal
NCT ID: NCT04862143 Org: User:
Start: 03/08/22 End: 09/19/22 Due: 09/19/23

Efficacy and Safety of LCZ696 Compared to Valsartan, on Morbidity and Mortality in Heart Failure Patients With Preserved Ejection Fraction

Phase: N/A Priority: Normal
NCT ID: NCT01920711 Org: User:
Start: 07/18/14 End: 06/07/19 Due: 06/07/20

Study of Patupilone in Patients With Brain Metastasis From Non-small Cell Lung Cancer

Phase: N/A Priority: Normal
NCT ID: NCT00219297 Org: User:
Start: 11/16/05 End: 06/24/10 Due: 06/24/11

An Open-label, Dose Escalation Study to Assess the Pharmacokinetics of of ASA404 in Adult Cancer Patients With Impaired Hepatic Function

Phase: N/A Priority: Normal
NCT ID: NCT01278849 Org: User:
Start: 01/31/10 End: - Due: -

Effectiveness and Safety of Dabrafenib in Combination With Trametinib as Adjuvant Treatment for Chinese Patients With Stage III BRAF V600 Mutation-positive Melanoma After Complete Resection

Phase: N/A Priority: Normal
NCT ID: NCT04666272 Org: User:
Start: 12/31/20 End: 07/31/29 Due: 07/31/30

EPO906 Therapy in Patients With Advanced Breast Cancer

Phase: N/A Priority: Normal
NCT ID: NCT00035126 Org: User:
Start: 01/31/02 End: 11/30/03 Due: 11/30/04

An Open Label Study to Evaluate the Pharmacokinetics, Safety, Tolerability and Efficacy of Deferasirox Administered to Chinese Patients With β-thalassemia Major Aged From 2 to Less Than 6 Years Old

Phase: N/A Priority: Normal
NCT ID: NCT01724138 Org: User:
Start: 06/30/13 End: 10/31/14 Due: 10/31/15

Study of EGF816 in Combination With Selected Targeted Agents in EGFR-mutant NSCLC

Phase: N/A Priority: Normal
NCT ID: NCT03333343 Org: User:
Start: 01/29/18 End: 10/20/25 Due: 10/20/26

NeoPHOEBE: Neoadjuvant Trastuzumab + BKM120 in Combination With Weekly Paclitaxel in HER2-positive Primary Breast Cancer

Phase: N/A Priority: Normal
NCT ID: NCT01816594 Org: User:
Start: 09/03/13 End: 02/18/15 Due: 02/18/16

Study Exploring the Effect of Crizanlizumab on Kidney Function in Patients With Chronic Kidney Disease Caused by Sickle Cell Disease

Phase: N/A Priority: Normal
NCT ID: NCT04053764 Org: User:
Start: 12/10/19 End: 03/20/23 Due: 03/20/24

Safety and Tolerability of HSC835 in Patients With Hematological Malignancies

Phase: N/A Priority: Normal
NCT ID: NCT01474681 Org: User:
Start: 01/09/12 End: 10/03/16 Due: 10/03/17